Transcatheter Technologies CEO Wolfgang Goetz said the new system has been designed to make aortic stenting more precise and safer.

"This coated endovascular stent allows for extraordinarily precise positioning and anchoring, thus making the treatment of more complex aortic disorders possible.

"Additionally, a short version of Tumbao can seal endoleaks between an existing aortic stent and the native aortic wall (endovascular aortic sealing)."

The firm’s product platform allows precision-controlled expansion and anchors self-expanding Nitinol stents to treat complex aortic aneurysm.

Transcatheter noted that thoracic or abdominal aortic aneurysm is a dilatation of the aortic vessel, which occurs in 2%-8% of patients older than 50 years.

The company develops and markets products for the treatment of structural heart diseases and aortic disorders.